What is the recommended deep vein thrombosis (DVT) prophylaxis for hospitalized patients?

DVT Prophylaxis in Hospitalized Patients

All hospitalized medical patients at increased risk for thrombosis should receive pharmacologic thromboprophylaxis with LMWH, low-dose unfractionated heparin (UFH), or fondaparinux throughout their hospitalization, unless they have active bleeding or other contraindications to anticoagulation. 1

Risk Stratification

High-Risk Medical Patients Requiring Prophylaxis

• Acutely ill hospitalized patients with reduced mobility 1
• Patients with active malignancy, even without additional risk factors 1
• Critically ill patients in intensive care units 1
• Patients with acute medical illness (heart failure, respiratory failure, infection, inflammatory conditions) 1

Low-Risk Patients NOT Requiring Prophylaxis

• Patients admitted solely for minor procedures or chemotherapy infusion 1
• Patients undergoing stem-cell/bone marrow transplantation 1
• Fully ambulatory patients without additional risk factors 1

Pharmacologic Prophylaxis Options

The choice between agents should be based on renal function, bleeding risk, and institutional factors: 1

• Enoxaparin: 40 mg subcutaneous once daily 1
• Dalteparin: 5,000 IU subcutaneous once daily 1
• UFH: 5,000 units subcutaneous twice or three times daily 1
• Fondaparinux: 2.5 mg subcutaneous once daily 1

LMWH is preferred over UFH due to once-daily dosing convenience and lower risk of heparin-induced thrombocytopenia, though UFH should be used in patients with severe renal impairment (creatinine clearance <30 mL/min). 1

Duration of Prophylaxis

Prophylaxis should be continued throughout the hospitalization and discontinued at discharge rather than extending beyond hospital discharge, as extended prophylaxis has not demonstrated benefit in general medical patients. 1

Mechanical Prophylaxis

Mechanical prophylaxis alone is NOT recommended as primary prevention in medical patients. 1

When to Use Mechanical Methods

• Patients at high risk for major bleeding where anticoagulation is contraindicated 1
• Use graduated compression stockings (30-40 mm Hg) or intermittent pneumatic compression 1
• Graduated compression stockings should NOT be used routinely as they have not proven effective and can cause skin damage 1
• When bleeding risk decreases, switch from mechanical to pharmacologic prophylaxis 1

Special Populations

Cancer Patients

All hospitalized cancer patients should receive pharmacologic thromboprophylaxis with UFH, LMWH, or fondaparinux unless contraindicated. 1

• Cancer patients face higher VTE risk and experience pulmonary embolism more frequently (22.2% vs 15.5% in non-cancer patients) 2
• Despite higher risk, cancer patients receive prophylaxis less often than non-cancer patients (25.4% vs 53.8%) 2

Surgical Cancer Patients

• Start prophylaxis before surgery and continue for at least 7-10 days postoperatively 1
• Consider extending prophylaxis up to 4 weeks after major abdominal or pelvic cancer surgery, especially with residual disease, obesity, or prior VTE history 1

Critically Ill Patients

• Use LMWH or LDUH over no prophylaxis 1
• If bleeding or high bleeding risk exists, use mechanical prophylaxis (graduated compression stockings or intermittent pneumatic compression) until bleeding risk decreases 1

Common Pitfalls

The most significant gap in practice is underutilization of prophylaxis. Only 58.5% of at-risk surgical patients and 39.5% of at-risk medical patients receive recommended prophylaxis, and only 42% of patients who develop DVT received prophylaxis within 30 days before diagnosis. 1

Do not use rivaroxaban for VTE prevention in acutely ill general medical patients outside of orthopedic surgery, as the MAGELLAN trial showed increased bleeding risk without clear benefit. 1

Avoid universal prophylaxis protocols that ignore individual patient risk assessment, as low-risk patients may experience more harm than benefit from anticoagulation. 1